cal care. What should clinicians do for patients whose diagnosis does not quite meet formal diagnostic criteria? What treatment works best for which patient? Which competing treatment should one choose? Should multiple treatments be started simultaneously or should treatments be given in sequence? How should comorbid conditions be addressed? When should medication be given to someone in distress when the distress is caused by severe psychosocial stress (such as bereavement)? When should a clinician declare that a treatment is failing? Should the trial be extended with the hope that some patients will eventually respond? What would be the optimal course of action after the first, second, third, or subsequent treatment fails? How does one best weigh benefits and risks, and integrate the clinician's perception of benefits and risks with the patient's perceptions? In addition to strategies (what to do), these questions also bring up tactical issues (how to do it) which are usually not covered in the literature. 3 When clinicians face tactical micro-decisions, they are frequently uncertain about the best course of action. With sufficient information from the literature, we can estimate the probability (and, perhaps, beyond point probability, the 95% confidence interval) of an outcome for the group that a patient belongs to, but not the probability of that patient's individual outcome. 4 Clinicians apply group data (nomothetic) from the literature to the particular data (ideographic) from individual patients and hope for the best outcome. 5 Few, if any, studies bring certainty to medical decision-making for any individual patient. Most clinical trials are designed to explain ("does the intervention change the target outcome?") rather than guide treatment ("does the intervention work when used in normal practice?"). 6 The problem is that results from explanatory trials are used for treatment decisions, which is not the purpose of explanatory trials.
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C N S Spectr 1 4 : 6 form patterns that become "practice-based medicine". Practice-based medicine, if done well, turns into clinical expertise characterized by fine-tuned decision making and can result in a greater frequency of good, as well as a decreased frequency of bad, outcomes. 9 These expert physicians are often sought out for their clinical judgment.
But individual clinicians can take care of a limited number of patients and, as a result, develop limited-expertise. Another limit arises from how clinicians make decisions. They frequently depend on heuristics formed from memories of clinical encounters biased by cognitive and emotional processes. 110 A heuristic is a categorical cognitive process that takes complex data and distills it into a simpler category that facilitates decision making. 1 Clinicians tend to use availability heuristics (what happened recently or what is most accessible to recall) to drive their decisions. Affect heuristics are those simple rules that arise from emotional responses to data (eg, anxiety and fear). 10 A single patient who develops fatal toxic epidural necrosis with lamotrigine will increase a clinician's estimate (and fear) that this side effect will occur again.
11
Clinicians' limited experience coupled with their imperfect memories and inherent biases of recall added to the all-too-human use of heuristics, compromises how clinicians use available evidence from practice-based medicine. One remedy is to integrate sensible systematic assessment, collection, and analysis of patient outcomes into practice. 12 Measurement-based care 13 coupled with systems to evaluate the data for individual and group outcomes could provide data that inform clinical practice beyond randomized controlled trials. Implementation of such systems presents a formidable challenge 14 and electronic medical records may be the answer if, and only if, they are designed and used correctly.
Even with the best evidence in hand, whether from randomized clinical trials, pragmatic effectiveness research, or practice-based evidence, uncertainty will persist. Results for different studies can be inconsistent and, as stated earlier, no study or set of studies will precisely describe individual patients. In addition, most studies are explanatory rather than pragmatic. 15 How can one use the plethora of available data and turn that into information, knowledge, and good judgment with sound medical decision-making? Perhaps the answer is in realizing that the process clinicians use to make clinical decisions is practical reasoning, also known as phronesis, an archaic term from Aristotle resurrected by Kathryn Excellent psychiatric and neuropsychiatric care, therefore, integrates the best available spectrum of evidence (with all of its flaws, biases, and uncertainties) with the best practical reasoning. It is this complex dance of evidence and phronesis that makes clinical psychiatry and neuropsychiatry such a challenging and rich intellectual endeavor. CNS
